Efficacy and safety of weekly paclitaxel combined with cetuximab in the treatment of pretreated recurrent/metastatic head and neck cancer patients

SummaryIntroductionThe addition of cetuximab to weekly paclitaxel has demonstrated high efficacy in the first-line treatment of patients with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M-SCCHN). However, this combination has been widely extended to patients who present resistance to first line chemotherapy (CT) or those who are not candidates for platinum-based CT.Material and methodsWe have retrospectively analyzed the efficacy and safety of cetuximab in combination with weekly paclitaxel in patients with R/M-SCCHN who present disease progression after platinum schedules or those who were not candidates for platinum-based CT. Patients received weekly paclitaxel 80 mg/m2 and cetuximab 250 mg/m2 (initial dose of 400 mg/m2) until progression or unacceptable toxicity.ResultsTwenty-two patients were included. Median age was 58 (43–68), ECOG PS (0/1/2): 6/10/4, 19 patients had received prior platinum-based treatment (nine patients were platinum-sensitive and nine were platinum-refractory). With a median follow-up of 6.18 months (range 1.3–29.7), overall response rate (ORR) was 55% (95% CI 31–76%):1 (5%) complete response and 9 (50%) partial responses. Median duration of response was 10.23 months. Median progression free survival (PFS) and overall survival (OS) were 5.4 and 9.1 months, respectively. There were no differences in response rate according to platinum sensitivity (66% sensitive vs 44% refractory; P = 0.61). The main toxicity consisted of rash in 70% of patients (5% grade 3), with an association between rash severity and ORR (grade 0–1: 33% vs grade 2–3: 64%; P = 0.03) and a trend for better PFS and OS.ConclusionWeekly paclitaxel in combination with cetuximab is a well tolerated and highly active second-line treatment in patients with R/MSCCHN who experience disease progression after platinum-based CT, including those who present resistant disease. Our results suggest that the efficacy of this combination is apparently superior than the published data on single agent cetuximab in this setting.